Dipyaman Ganguly , M.B.B.S, Ph.D., Ph.D.

Senior Scientist
Cancer Biology & Inflammatory Disorder

Research Focus

Immunology, Innate Immunity, Dendritic cells, Autoimmune disorders, Metabolic syndrome, Mechanosensors, T cells, B cells

Research Interest

The basic premise for immune algorithm is distinguishing self from nonself. This is achieved by different modules of host immune system. The ‘innate’ immune system recognizes the nonself based on predominantly nonself-associated molecular patterns (PAMPs), while the ‘adaptive’ immune axis adapts to the nonself molecular determinants. These two work together toward an effective immune response. An effective immune response to an invading pathogen (nonself) leads to protective immunity and a defective response leads to overt infection. On the other hand, an unintended response to the self-entities leads to autoimmune disorders, while a misjudged tolerance to the altered self contributes to tumorigenesis. Our research broadly concentrates on role of innate immune axis in the crossroads of infection, autoimmunity and cancer. Dendritic cells (DCs) are the innate cells with most of the decision-making responsibilities for an ensuing immune response or tolerance. We try to decipher the governing principles of self-nonself discrimination by the germline-encoded invariant pattern recognition receptors (PRRs) expressed by DCs and how they work in a given clinical context. Broadly the research directions of our lab are:

  • Innate immune regulation and molecular mechanisms of dendritic cell function
  • Role of innate immune deregulation in autoreactive inflammation
  • Deciphering the role and modulation of dendritic cells in tumor microenvironment
  • History and philosophy of self-nonself recognition


Ours is a relatively new laboratory in IICB (located in the IICB-Translational Research Unit of Excellence, Salt Lake Campus) that promises a lot of fun and exciting science, which will be achieved through hard work of all its members. Feel free to contact Dipyaman if you feel like sharing the excitement.


  • PhD in Immunology and Biomedical Science, UT MD Anderson Cancer Center, Houston, USA, 2010
  • PhD in Biotechnology, Indian Institute of Chemical Biology, Kolkata, India, 2008
  • MBBS, Medical College & Hospitals, Calcutta, India, 2001

Honours & Awards

  1. National Bioscience Award for Career Development, from Department of Biotechnology, Govt. of India, 2017/18.
  2. CDRI Award for Excellence in Drug Research, from CSI-Central Drug Research Institute, India, 2019.
  3. Swarnajayanti Fellowship in Life Sciences, from Dept. of Science & Technology, Govt. of India, 2017.
  4. NASI Scopus Young Scientist Award in Medicine, from National Academy of Science India and Elsevier, 2017.
  5. Ramanujan Fellowship, Dept. of Science & Technology, Govt. of India, 2013.
  6. Lupus Foundation Postdoctoral Fellowship from S.L.E. Foundation, New York, 2011.
  7. Keystone Symposium Scholarship, 2009.
  8. Vivian L. Smith Outstanding Young Immunologist Award from the Center for Cancer Immunology Research, UT MD Anderson Cancer Center, Houston, Texas, USA, 2007.

Grants & Supports

Projects being implemented



Funded by



(Lakh INR)

Brief description



Ramanujan Fellowship




(5 yrs,


Start-up grant to initiate laboratory, used for the project where we discovered a critical role of plasmacytoid dendritic cells and type I IFNs in obesity associated insulin resistance (Ghosh et al, Diabetes, 2016; Nargis et al., Mol Metab, 2017; Ganguly, Trends Immunol, 2018)



Probing endosomal toll-like receptor 9 biology using novel small molecule antagonists




(3 yrs,


Gaining structural insight into TLR9 antagonism using small molecules and development of novel small molecule antagonists of toll-like receptor 9 (Roy et al, Eur J Med Chem, 2017; 2 Patents)


Role of type I interferons in cerebral malaria




(3 yrs,


Deciphering the role of type I IFNs in protective immunity in a preclinical model of cerebral malaria, to understand pDC biology at the crossroads of autoimmunity and protective immunity


Exploring therapeutic efficacy of novel toll-like receptor 9 antagonists in type 2 diabetes




(2 yrs,


Pharmacokinetics, toxicity and preclinical efficacy of novel small molecule TLR9 antagonists in preclinical model of diet-induced obesity


Indo-Australia Collaborative project on drug discovery for neglected diseases

(Australian PI: Jonathan Bael, Monash University)




(3 yrs, 2017-2019)

Pharmacodynamics and immunomodulatory activity of novel anti-parasitic small molecules.


Swarnajayanti Fellowship



227.0 (5 years, 2018-2022)

Mechanistic exploration of metabolic syndrome and development of novel therapies

Patents & Publications


  1. Inhibitors of phosphatidylinositol-3-kinase and nitric oxide.
    • US Patent 9290473, 2016.
    • EP Patent 2385934.
  2. Blocking toll-like receptor 9 signalling using small molecule antagonists. 
    • Indian Patent Application No. 201611009670, March 21, 2016.
    • International Patent Application No. PCT/IN/2017/050103, March 21, 2017.
  3. Purine derivatives as toll-like receptor 9 antagonists. 
    • Provisional Patent Application CSIR Ref No. 0034NF2017, 2017.



  1. Mukhopadhyay S, Dutta D, Ganguly D. Psoriasis and Diabetes: An association likely missed. Book chapter in 'Psoriasis and Psoriatic Arthritis: Pathophysiology and Therapeutic Interventions' 1st edition 2018, Taylor & Francis.
  2. Mukhopadhyay S, Dutta D, Ganguly D. Lipid induced insulin resistance: Molecular Mechanisms and Clinical Implications. Book chapter in ‘Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome' 2nd edition 2018, Elsevier.



  1. Raychaudhuri D, Bhattacharya R, Sinha BP, Liu CSC, Ghosh AR, Rahaman O, Bandopadhyay P, Sarif J, D'Rozario R, Paul S, Das A, Sarkar DK, Chattopadhyay S, Ganguly D. Lactate Induces Pro-Tumor Reprogramming in Intratumoral Plasmacytoid Dendritic Cells. Frontiers in Immunology, 2019. https://doi.org/10.3389/fimmu.2019.01878
  2. Liu CSC, Ganguly D. Mechanical Cues for T Cell Activation: Role of Piezo1 Mechanosensors. Critical Reviews in Immunology, 2019, 39 (1): 15-38.
  3. Rahaman O, Bhattacharya R, Liu CSC, Raychaudhuri D, Ghosh AR, Bandopadhyay P, Pal S, Goswami RP, Sircar G, Ghosh P, Ganguly D. Cutting Edge: Dysregulated endocannabinoid-rheostat for plasmacytoid dendritic cell activation in a systemic lupus endophenotype. Journal of Immunology, 2019 Mar 15;202(6):1674-1679.
  4. Liu CSC, Raychaudhuri D, Paul B, Chakrabarty Y, Ghosh AR, Rahaman O, Talukdar A, Ganguly D. Cutting Edge: Piezo1 Mechanosensors Optimize Human T Cell Activation. Journal of Immunology. 2018 Jan 12. pii: ji1701118.
  5. Nargis T, Kumar K, Ghosh AR, Sharma A, Rudra D, Sen D, Chakrabarti S, Mukhopadhyay S, Ganguly D, Chakrabarti P (#Corresponding authors). KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes. Molecular Metabolism. 2017 Nov;6(11):1529-1539.
  6. Ganguly D. Do type I interferons link systemic autoimmunities and metabolic syndrome in a pathogenetic continuum? Trends in Immunology. 2018 Jan;39(1):28-43.
  7. Roy S, Mukherjee A, Paul B, Rahaman O, Roy S, Maithri G, Ramya B, Pal S, Ganguly D#, Talukdar A# (#Corresponding authors). Design and Development of benzoxazole derivatives with toll-like receptor 9 antagonism. European Journal of Medicinal Chemistry. 2017. 134:334-347.
  8. Ghosh AR, Bhattacharya R, Bhattacharya S, Nargis T, Rahaman O, Duttagupta P, Raychaudhuri D, Chen Liu CS, Roy S, Ghosh P, Khanna S, Chaudhuri T, Tantia O, Haak S, Bandyopadhyay S, Mukhopadhyay S, Chakrabarti P, Ganguly D. Adipose Recruitment and Activation of Plasmacytoid Dendritic Cells Fuel Metaflammation. Diabetes. 2016. 65 (11): 3440-3452. (In media: http://indianexpress.com/article/lifestyle/health/why-the-obese-are-prone-to-diabetes-a-protein-gives-a-clue/; http://www.ndtv.com/health/indian-scientists-discover-link-between-obesity-diabetes-1455710 ; http://www.hindustantimes.com/health-and-fitness/why-does-obesity-cause-diabetes-indian-scientists-just-found-an-explanation/story-M2ExSvGoD4DjjSodszeVrL.html ; http://www.anandabazar.com/lifestyle/do-we-get-diabetic-with-the-increase-of-fat-1.476272# ; https://www.telegraphindia.com/1160908/jsp/nation/story_107007.jsp#.WN9XljuGPIW )
  9. Meller S, Di Domizio J, Voo KS, Friedrich HC, Chamilos G, Ganguly D, Conrad C, Gregorio J, Le Roy D, Roger T, Ladbury JE, Homey B, Watowich S, Modlin RL, Kontoyiannis DP, Liu YJ, Arold ST, Gilliet M. T helper 17 cells promote microbial killing and innate immune sensing of DNA via interleukin-26. Nature Immunology. 2015. 16(9):970-9.
  10. Sisirak V*, Ganguly D*, Lewis KL, Couillault C, Tanaka L, Bolland S, D’Agati V, Elkone KB, Reizis B (*equal contribution). Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus. Journal of Experimental Medicine. 2014. 211(10):1969-76.
  11. Ganguly D, Haak S, Sisirak V, Reizis B. Role of dendritic cells in autoimmunity. Nature Reviews Immunology. 2013. 13(8):566-77.
  12. Di Domizio J, Dorta-Estremera S, Gagea M, Ganguly D, Meller S, Li P, Zhao B, Tan FK, Bi L, Gilliet M, Cao W. Nucleic acid-containing amyloid fibrils potently induce type I interferon and stimulate systemic autoimmunity. Proc Natl Acad Sci U S A. 201. 109(36):14550-5.
  13. Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, Meller S, Chamilos G, Sebasigari R, Riccieri V, Bassett R, Amuro H, Fukuhara S, Ito T, Liu YJ, Gilliet M. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Science Translational Medicine. 2011. 3(73):73ra19. (Commentary in New England Journal of Medicine, 2011, 365(8):758-60; featured in Nature Reviews Key Advances in Medicine, 2012.)
  14. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, Facchinetti V, Homey B, Barrat FJ, Zal T, Gilliet M. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. Journal of Experimental Medicine. 2009. 206(9):1983-94.